Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus
Models, Molecular
0301 basic medicine
Microbial Sensitivity Tests
Crystallography, X-Ray
Antiviral Agents
Article
2-dihydrotriazine derivatives
Structure-Activity Relationship
03 medical and health sciences
Influenza A Virus, H1N1 Subtype
6-diamino-1
Humans
1-Aryl-4
1-Aryl-4,6-diamino-1,2-dihydrotriazine derivatives; Anti-RSV activity; Anti-influenza A and B viruses activity; Host (human) DHFR inhibition
Anti-RSV activity
Dose-Response Relationship, Drug
Molecular Structure
Triazines
Host (human) DHFR inhibition
Respiratory Syncytial Viruses
3. Good health
Influenza B virus
Tetrahydrofolate Dehydrogenase
Proguanil
1-Aryl-4,6-diamino-1,2-dihydrotriazine derivatives; Anti-influenza A and B viruses activity; Anti-RSV activity; Host (human) DHFR inhibition
1-Aryl-4,6-diamino-1,2-dihydrotriazine derivatives; Anti-influenza A and B viruses activity; Anti-RSV activity; Host (human) DHFR inhibition; Antiviral Agents; Crystallography, X-Ray; Dose-Response Relationship, Drug; Folic Acid Antagonists; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Proguanil; Respiratory Syncytial Viruses; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Triazines; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry
Folic Acid Antagonists
1-Aryl-4,6-diamino-1,2-dihydrotriazine derivatives, Anti-influenza A and B viruses activity, Anti-RSV activity, Host (human) DHFR inhibition
Anti-influenza A and B viruses activity
DOI:
10.1016/j.ejmech.2017.04.070
Publication Date:
2017-04-27T17:48:21Z
AUTHORS (9)
ABSTRACT
We have identified a series of 1-aryl-4,6-diamino-1,2-dihydrotriazines, structurally related to the antimalarial drug cycloguanil, as new inhibitors of influenza A and B virus and respiratory syncytial virus (RSV) via targeting of the host dihydrofolate reductase (DHFR) enzyme. Most analogues proved active against influenza B virus in the low micromolar range, and the best compounds (11, 13, 14 and 16) even reached the sub-micromolar potency of zanamivir (EC50 = 0.060 μM), and markedly exceeded (up to 327 times) the antiviral efficacy of ribavirin. Activity was also observed for two influenza A strains, including a virus with the S31N mutant form of M2 proton channel, which is the most prevalent resistance mutation for amantadine. Importantly, the compounds displayed nanomolar activity against RSV and a superior selectivity index, since the ratio of cytotoxic to antiviral concentration was >10,000 for the three most active compounds 11, 14 and 16 (EC50 ∼0.008 μM), far surpassing the potency and safety profile of the licensed drug ribavirin (EC50 = 5.8 μM, SI > 43).
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (30)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....